2 recruiting, 1 active not recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow MELPIDA: new trials by email Literature Review of MELPIDA trials Research Report on MELPIDA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls. MELPIDA - Hereditary Spastic Paraplegia Type 50 | Phase 3 | Recruiting | Elpida Therapeutics SPC | 24 | 2026-04-01 | 2026-04-20 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
| Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50 MELPIDA - Spastic Paraplegia Type 50 | Phase 1 | Active not recruiting | The Hospital for Sick Children | 1 | 2022-03-11 | 2025-05-14 |
Paraplegia (2) · Microcephaly (1) · Muscle Spasticity (1)
Elpida Therapeutics SPC (2) · The Hospital for Sick Children (1)
United States (2) · Canada (1) · Spain (1)
Susan T. Iannaccone, MD, FAAN (1)